Summit Therapeutics PLC 55336VAL4 Bond
SMMT Stock | USD 18.94 0.26 1.35% |
Summit Therapeutics PLC holds a debt-to-equity ratio of 0.032. At this time, Summit Therapeutics' Long Term Debt To Capitalization is comparatively stable compared to the past year. Total Debt To Capitalization is likely to gain to 0.62 in 2024, whereas Interest Debt Per Share is likely to drop 0.14 in 2024. . Summit Therapeutics' financial risk is the risk to Summit Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Summit Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Summit Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Summit Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Summit Therapeutics' stakeholders.
For most companies, including Summit Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Summit Therapeutics PLC, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Summit Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 32.3324 | Book Value 0.594 | Return On Assets (0.31) | Return On Equity (0.73) |
Summit |
Given the importance of Summit Therapeutics' capital structure, the first step in the capital decision process is for the management of Summit Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Summit Therapeutics PLC to issue bonds at a reasonable cost.
Popular Name | Summit Therapeutics MPLX LP 52 |
Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
Equity ISIN Code | US86627T1088 |
Bond Issue ISIN Code | US55336VAL45 |
S&P Rating | Others |
Maturity Date | 1st of March 2047 |
Issuance Date | 10th of February 2017 |
Coupon | 5.2 % |
Summit Therapeutics PLC Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
International Game Technology | US460599AD57 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
Valero Energy Partners | US91914JAA07 | Details |
Understaning Summit Therapeutics Use of Financial Leverage
Summit Therapeutics' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Summit Therapeutics' current equity. If creditors own a majority of Summit Therapeutics' assets, the company is considered highly leveraged. Understanding the composition and structure of Summit Therapeutics' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last Reported | Projected for Next Year | ||
Net Debt | 34.7 M | 36.4 M | |
Short and Long Term Debt Total | 106.1 M | 111.4 M | |
Short Term Debt | 2.8 M | 4 M | |
Long Term Debt | 100 M | 109 M | |
Short and Long Term Debt | 22.7 M | 23.9 M | |
Net Debt To EBITDA | 34.64 | 36.37 | |
Debt To Equity | 1.29 | 1.35 | |
Interest Debt Per Share | 0.19 | 0.14 | |
Debt To Assets | 0.49 | 0.52 | |
Long Term Debt To Capitalization | 0.56 | 0.79 | |
Total Debt To Capitalization | 0.56 | 0.62 | |
Debt Equity Ratio | 1.29 | 1.35 | |
Debt Ratio | 0.49 | 0.52 | |
Cash Flow To Debt Ratio | (0.77) | (0.81) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.